Physicians’ Education Resource® to Hold 4th Annual International Congress on Immunotherapies in Cancer®: Focus on Practice-Changing Application

On September 3, 2019 Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education, reported that it will present the 4th Annual International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application on Saturday, Dec. 14, at the InterContinental New York Times Square in New York City (Press release, Physicians’ Education Resource, SEP 3, 2019, View Source [SID1234539237]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program will be co-chaired by Naiyer A. Rizvi, M.D., professor of medicine; director, thoracic oncology; co-director, cancer immunotherapy program; and the Price Family Professor of Medicine, Columbia University Medical Center; and Mario Sznol, M.D., professor of medicine; leader, melanoma disease related translational team; co-director, YALE SPORE in skin cancer; and co-director, cancer immunology program, Yale Cancer Center.

"We look forward to this year’s International Congress on Immunotherapies in Cancer," said Phil Talamo, president of PER. "This annual educational program brings together oncologists, nurses and pharmacists to highlight the fundamental principles and pivotal advancements within the past year surrounding the evolving role of immunotherapies and their role in cancer treatment."

The 4th Annual International Congress on Immunotherapies in Cancer is a one-day interactive program that will provide attendees with a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. Top experts will lead discussions that focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings and the most highly anticipated clinical trials in the field. As an exciting, fast-paced congress, this meeting will provide a multimodule, curriculum-based program that focuses exclusively on immunotherapies and their application to the management of cancer.